Business
Theralase Commences Collaborative Research with National Microbiology Laboratory for Development of Coronavirus Vaccine
TORONTO, ON / ACCESSWIRE / April 9, 2021 / Theralase ® Technologies Inc. (" Theralase ...
About this update from Theralase Technologies Inc.
[{"type":"text","content":"Theralase Commences Collaborative Research with National Microbiology Laboratory for Development of Coronavirus VaccineTORONTO, ON / ACCESSWIRE / April 9, 2021 / Theralase® Technologies Inc. (\"Theralase\" or the \"Company\") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (\"PDC\") and their associated drug formulations to safely and effectively destroy various cancers, bacteria and viruses, announced today that it has executed a Collaborative Research Agreement (\"CRA\") with the National Microbiology Laboratory, Public Health Agency of Canada (\"PHAC\") for the research and development of a Canadian-based SARS-CoV-2 (\"COVID-19\") vaccine.Under the terms of the agreement, Theralase® and PHAC are collaborating on the development and optimization of a COVID-19 vaccine by treating the SARS-CoV-2 virus grown on cell lines with Theralase®'s patented PDC and then light activating it with Theralase®'s proprietary TLC-3000A light technology to inactivate the virus and create the fundamental building blocks of a COVID-19 vaccine. This inactivated virus would then be purified and used to inoculate naive animals followed by challenge with the SARS-CoV-2 virus, to ascertain the efficacy of the vaccine. The project is entitled, \"Photo Dynamic Compound Inactivation of SARS-CoV-2 Vaccine\" and is expected to commence in mid-April 2021.PHAC is a world leader in vaccine creation and has a long history of vaccine development. PHAC scientists developed the world's first approved Ebola vaccine (Ervebo), which the Government of Canada donated to the World Health Organization (\"WHO\") during the height of the 2014-16 Ebola outbreak and in the process helped to save countless lives in Africa.Darwyn Kobasa, Ph.D., Head, High Containment Respiratory Virus Group, Special Pathogens, PHAC/NML, stated \"Our research expertise will help assist Theralase® to research and develop an effective COVID-19 vaccine that is robust enough to vaccinate against the main phenotype of the disease and its emerging variants. NML has unique capacity to conduct preclinical research in animal models, that must occur in high containment laboratory space, which is essential to the development of an effective COVID-19 vaccine. I am delighted for having...